

> COMPANY OVERVIEW

Tissue Genesis, an emerging leader in adipose-derived cell therapy and regenerative medicine, is a clinical-stage company in the high-growth field of regenerative medicine.

Tissue Genesis has received approval from the United States Food and Drug Administration to initiate a clinical trial for the treatment of peripheral vascular disease using adipose (fat) derived stem cells.

> TISSUE GENESIS' REGENERATIVE THERAPIES - A CLOSER LOOK

Tissue Genesis focuses on using a patient's own adipose (fat) derived stem cells (ASCs) to treat many severe and previously untreatable conditions such as heart disease, vascular disease, orthopedic and spine injury, and soft tissue and reconstructive repair. Adipose tissue is an easily accessible and rich source of adult stem cells, and utilizing the Tissue Genesis Cell Isolation System, tens of millions of ASCs may be harvested in one hour

at the point-of-care. These cells can be used at the site of injury or disease, and may amplify the body's own repair process.

The Tissue Genesis Cell Isolation System is a fully automated and easy-to-use operating room ready, CE-marked, good manufacturing practices developed, instrument that fits easily into any clinical environment, and is ready for use in a variety of applications.

> RECENT DEVELOPMENTS AT TISSUE GENESIS

- Tissue Genesis received approval from the United States Food and Drug Administration (FDA) to pursue a clinical trial for the Tissue Genesis Vascular Graft, using the Tissue Genesis Cell Isolation System™, which is currently underway at the University of Louisville's Cardiovascular Innovation Institute under Dr. Stuart Williams.

- World renowned Dr. Kotaro Yoshimura of the University of Tokyo, in collaboration with Tissue Genesis, has completed a 20 patient clinical study in Tokyo, Japan for facial and breast reconstructive and cosmetic surgeries. Tissue Genesis is funding an additional 20 patients to further demonstrate the utility of ASCs for improved plastics and reconstructive use.

- Tissue Genesis also signed an agreement with American Medical Systems Holdings Inc. (NASDAQ: AMMD), a large cap company, for the use of Tissue Genesis' technologies in treating pelvic health disorders.

- The U.S. Department of Defense awarded a \$3.41 Million contract to Tissue Genesis, Inc. to continue its research and development activities, focusing on Clinical Validation of Adipose-Derived Regenerative Cells for Tissue Repair. Tissue Genesis has a proven history with over \$25 Million received through seven contracts from the government since 2002. Funding for the company's next contract, expected in 2011, is already in process.

> ABOUT TISSUE GENESIS

An emerging leader in adipose-derived cell therapy and regenerative medicine, **Tissue Genesis, Inc.** is a high-growth, clinical-stage company based in Honolulu, Hawai'i. Industry-leading engineers and scientists have developed a proprietary process for Tissue Genesis that promote innovative medical solutions for a wide range of existing medical problems, including: cardiac and peripheral vascular disease; orthopedic injuries; aesthetic and soft tissue defects; and many other applications.

Thanks to Tissue Genesis, it is believed smart, safe and ethical regenerative therapies will improve the quality of life for patients and their families. For more information, please visit www.tissuegenesis.com.

THE TISSUE GENESIS CELL ISOLATION SYSTEM HAS NOT BEEN EVALUATED BY THE US FDA FOR HUMAN USE.

[tissue genesis inc.](http://www.tissuegenesis.com)

An Emerging Leader in Adipose-Derived Cell Therapy and Regenerative Medicine

677 Ala Moana Blvd. Suite 1100, Honolulu, Hawai'i 96813 || (808) 539-9331 || info@tissuegenesis.com || www.tissuegenesis.com